Phase II study of Durvalumab (MEDI4736) Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients (Dolphin study: WJOG11619L Investigator-Initiated Clinical Trial)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms Dolphin study; WJOG11619L

Most Recent Events

09 Aug 2022 Primary endpoint progression free survival rate at 12 months has been met according to results presented at the 2022 World Conference on Lung Cancer
09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer
17 Dec 2021 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight